Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in healthy Asian and Caucasian volunteers
NCT02596217Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2015
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of risankizumab in plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease and 1 more (8 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of subjects with drug-related adverse events at 144 days. Started Aug 2015; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02596217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596217.